February 17, 2015 | According to reports, the Chinese pharmaceutical company Fosun Pharma is interested in acquiring Israeli aesthetic medicine company Lumenis. Foshun Pharma, which owns one of Lumenis’ Israeli competitors Alma Lasers, has apparently begun to approach shareholders regarding a possible deal. Lumenis is traded at a market-cap of $380 million and is run by Tzipi Ozer-Armon.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments